Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28498)	3/9/1999 10:04:00 PM
From: Machaon	Respond to of 32384

Bob, I couldn't find a current evaluation on Henry's site. Perhaps I didn't know where to look. But, I did look back into this thread and found an interesting post #28097 by David A. Kincade. Ligand is just such a big hairy beast that it is very difficult to evaluate. In spite of the delay, I have a lot of confidence in the Lilly/Ligand diabetes program. Lilly and Ligand must've seen a lot of value in the second generation retinoids, as is obvious by Lilly continuing the program. Unfortunately, to go back to pre-clinical status on the diabetes program is a real disappointment.